228 studies found for:    "Mesothelioma"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
Conditions: Recurrent Malignant Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Biological: oncolytic measles virus encoding thyroidal sodium iodide symporter;   Other: laboratory biomarker analysis;   Procedure: single photon emission computed tomography;   Procedure: computed tomography
2 Active, not recruiting Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
Conditions: Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Drug: tivantinib;   Other: laboratory biomarker analysis
3 Completed Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
Conditions: Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma;   Stage IA Malignant Mesothelioma;   Stage IB Malignant Mesothelioma;   Stage II Malignant Mesothelioma;   Stage III Malignant Mesothelioma;   Stage IV Malignant Mesothelioma
Interventions: Drug: sorafenib tosylate;   Other: laboratory biomarker analysis
4 Completed Gefitinib in Treating Patients With Malignant Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis
5 Active, not recruiting
Has Results
Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Localized Malignant Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Intervention: Drug: cediranib maleate
6 Withdrawn AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Biological: rilotumumab;   Drug: cisplatin;   Drug: pemetrexed disodium;   Other: laboratory biomarker analysis
7 Recruiting Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: pemetrexed disodium;   Drug: cisplatin;   Drug: cediranib maleate;   Other: placebo
8 Completed Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis
9 Completed PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: belinostat;   Other: laboratory biomarker analysis
10 Completed
Has Results
Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Localized Malignant Mesothelioma;   Recurrent Malignant Mesothelioma
Interventions: Other: laboratory biomarker analysis;   Drug: pazopanib hydrochloride
11 Recruiting Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
Conditions: Mesothelioma;   Pleural Mesothelioma
Interventions: Drug: Pemetrexed;   Drug: Cisplatin
12 Active, not recruiting
Has Results
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy
Conditions: Pleural Mesothelioma;   Peritoneal Mesothelioma
Intervention: Drug: IMC-A12
13 Completed Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelial Mesothelioma;   Localized Malignant Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatous Mesothelioma
Interventions: Drug: gemcitabine hydrochloride;   Drug: cisplatin;   Biological: bevacizumab;   Other: placebo;   Other: laboratory biomarker analysis
14 Completed
Has Results
Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Recurrent Malignant Mesothelioma
Intervention: Drug: sunitinib malate
15 Completed Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma
Conditions: Pleural Mesothelioma;   Malignant Pleural Mesothelioma
Interventions: Drug: Cisplatin;   Drug: Sodium Thiosulfate
16 Active, not recruiting Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
Condition: Mesothelioma
Interventions: Drug: Cisplatin;   Drug: Imatinib Mesylate;   Drug: Pemetrexed
17 Recruiting Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Condition: Mesothelioma
Intervention:
18 Recruiting Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
Condition: Mesothelioma
Intervention:
19 Active, not recruiting SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
Condition: Mesothelioma
Interventions: Drug: SS1P;   Drug: Pemetrexed;   Drug: Cisplatin
20 Recruiting Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
Condition: Mesothelioma
Intervention: Drug: Velcade (bortezomib) plus Eloxatin (oxaliplatin)

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years